Does Rallies show Form 4 insider transactions for CPRX?

Yes. Rallies tracks CPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CPRX. It does not provide personalized investment advice.

CPRX (Catalyst Pharmaceuticals) Stock Analysis - Insider Trades

Catalyst Pharmaceuticals (CPRX) is a publicly traded Healthcare sector company. As of May 20, 2026, CPRX trades at $31.05 with a market cap of $3.82B and a P/E ratio of 17.25. CPRX moved -0.03% today. Year to date, CPRX is +34.82%; over the trailing twelve months it is +26.72%. Its 52-week range spans $19.05 to $32.56. Analyst consensus is buy with an average price target of $33.10. Rallies surfaces CPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CPRX stock inside the company?

Recent CPRX insider activity includes Harper Molly sold 15.53K, Harper Molly sold 4.47K, Harper Molly sold 6.75K, Del Carmen Jeffrey sold 10.98K, and Elsbernd Brian bought 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CPRX Key Metrics

Key financial metrics for CPRX
Metric	Value
Price	$31.05
Market Cap	$3.82B
P/E Ratio	17.25
EPS	$1.81
Dividend Yield	0.00%
52-Week High	$32.56
52-Week Low	$19.05
Volume	2.75M
Avg Volume	0
Revenue (TTM)	$596.96M
Net Income	$221.32M
Gross Margin	85.96%

Recent CPRX Insider Trades

Harper Molly sold 15.53K (~$360.20K) on Dec 12, 2025.
Harper Molly sold 4.47K (~$106.16K) on Dec 12, 2025.
Harper Molly sold 6.75K (~$155.56K) on Dec 12, 2025.
Del Carmen Jeffrey sold 10.98K (~$256.24K) on Nov 26, 2025.
Elsbernd Brian bought 40.00K (~$908.00K) on Nov 12, 2025.

Latest CPRX News

Catalyst Pharmaceuticals' $31.50 Share Deal Faces Fairness Probe — May 19, 2026
Catalyst Pharmaceuticals Q1 Revenues Rise 5.6% to $149.3M as AGAMREE Jumps 66.6% — May 11, 2026
Angelini to Buy Catalyst Pharmaceuticals for $4.1 Billion at 70% Premium — May 11, 2026
Law Firm Probes Catalyst Pharmaceuticals’ $31.50-Per-Share Sale to Angelini Pharma — May 8, 2026
Angelini Pharma to Buy Catalyst for $4.1 B, 21% Premium at $31.50 — May 8, 2026

CPRX Analyst Consensus

7 analysts cover CPRX: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $33.10.

Common questions about CPRX

Who is trading CPRX stock inside the company?: Recent CPRX insider activity includes Harper Molly sold 15.53K, Harper Molly sold 4.47K, Harper Molly sold 6.75K, Del Carmen Jeffrey sold 10.98K, and Elsbernd Brian bought 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CPRX?: Yes. Rallies tracks CPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CPRX. It does not provide personalized investment advice.